



# Financial Tear Sheet

## Corporate Profile


MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy —hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM.

## Stock Information

### MYOK (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$47.70</b>
Change (%)	▼ 0.55 (1.14%)
Volume	228,361
52 Week Low	\$12.20
Market Cap	\$1,892,401,241
Rolling EPS	-1.54
PE Ratio	0
Shares Outstanding	39,672,982

Data as of 05/25/18 4:00 p.m. ET



## Recent Press Releases

**05/22/18**

MyoKardia Announces Pricing of Public Offering of Common Stock

**05/21/18**

MyoKardia Announces Proposed Public Offering of Common Stock























**05/21/18**

















## Upcoming Events

There are currently no events scheduled.

## SEC Filings

<< First | Previous | Next | Last >>

Filing Date	Form	Description	Filing Group	Downloads
05/23/18	8-K	Report of unscheduled material events or corporate event	Current Reports	   
05/23/18	424B5	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	Registration Statements	   
05/21/18	424B5	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	Registration Statements	   
05/21/18	8-K	Report of unscheduled material events or corporate event	Current Reports	   
05/08/18	10-Q	Quarterly report which provides a continuing view of a company's financial position	Quarterly Filings	   
05/08/18	8-K	Report of unscheduled material events or corporate event	Current Reports	   

05/08/18	SC 13G/A	An amendment to the SC 13G filing	Other				
05/07/18	4	Statement of changes in beneficial ownership of securities	3,4,5				
05/07/18	4	Statement of changes in beneficial ownership of securities	3,4,5				
04/17/18	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	Proxy Filings				

<< First | Previous | Next | Last >>

## Corporate Governance

Tassos Gianakakos      Chief Executive Officer

Jonathan Fox, M.D., Ph.D. Chief Medical Officer

Jake Bauer                      Vice President, Business Development and Business Operations

Ingrid Boyes                      Senior Vice President, Human Resources

Steven Chan                      Vice President, Corporate Controller

Joseph Lambing, Ph.D.      Senior Vice President, Nonclinical and Pharmaceutical Development

Robert McDowell              Senior Vice President of Drug Discovery

Iris Roth, Ph.D.                      Vice President, Program Team Leader